Hologic vs. Minerva Surgical: A Procurement Manager's Guide to the Verdict and What It Means for Your OR Budget

Let's cut the legal drama and talk about what the Minerva Surgical v. Hologic verdict actually means for someone like me—a procurement manager staring down an annual budget for surgical devices. I've spent the last six years tracking every invoice, negotiating with vendors, and building cost models for a mid-sized hospital system. When this case hit the news, my first thought wasn't about patents or damages. It was: "What does this tell me about vendor risk and long-term pricing stability?"

Most of the coverage frames this as a David vs. Goliath story or a patent law textbook example. That's not helpful if you're trying to decide whether to commit to a five-year contract for a specific device platform. What I want to do here is break this down from a procurement perspective: what the verdict reveals about these two companies, and how that should influence your vendor evaluation process.

Let's rephrase that: this isn't about who "won" or "lost" in court. It's about what the case exposed about each company's approach to innovation, intellectual property, and long-term partnership—factors that directly impact your total cost of ownership.

The Verdict in Two Sentences (No Legal Jargon)

In January 2025, a jury found that Minerva Surgical's endometrial ablation system infringed on a Hologic patent. Minerva was ordered to pay $43.5 million in damages. Hologic also won on several other claims, including trade secret misappropriation.

If I remember correctly, the jury deliberated for about two days before reaching this decision. The legal specifics are complex, but the core takeaway is straightforward: the court backed Hologic's claim that Minerva used technology that Hologic had patented first.

(Should mention: this is specific to the NovaSure and Minerva's Symphony system. It doesn't cover all of Minerva's product line, just their core endometrial ablation device.)

What This Means for Your Vendor Evaluation (Three Dimensions)

Dimension 1: Innovation and R&D Investment

Here's the direct comparison. Hologic has a massive R&D operation—I'd estimate they spend north of $200 million annually across their entire portfolio. They've been in the women's health surgical space for decades. Minerva, by contrast, is a smaller player. They built a system that they positioned as a next-generation alternative to Hologic's NovaSure.

When I compared our vendor profiles side by side for a different product category last year—established market leader vs. challenger—I realized the challenger was offering a lower price but their technology roadmap was basically a copy of the leader's. The leader had the R&D history to prove their product would still be relevant in 5 years. The challenger? I couldn't find the same depth of clinical evidence or patent portfolio.

Seeing this case play out made me realize that the patent landscape is a legitimate procurement concern. If you're buying equipment from a company whose core product is being challenged on IP grounds, you're taking on risk. What happens if they lose the case and have to pull the product? You're stuck with orphaned equipment and training that's no longer relevant.

Dimension 2: Vendor Stability and Pricing Predictability

It's tempting to think that a lower-priced challenger is the better deal. But the Minerva case shows how quickly the landscape can change. A $43.5 million judgment against a company of that size is significant. It's not a death blow, but it affects their operating cash flow, their ability to invest in new products, and their R&D pipeline.

Most buyers focus on unit pricing and completely miss the financial health of the vendor. I built a cost calculator after getting burned on hidden fees twice with a vendor that later went under. The 'cheap' option resulted in a $1,200 redo when quality failed and we had to find a replacement. The question everyone asks is 'what's your best price?' The question they should ask is 'what's your company's financial runway?'

Oh, and this isn't about being alarmist. Minerva isn't going anywhere tomorrow. But the verdict changes their cost structure. They now have legal fees, potential license payments, or a product redesign to fund. Those costs don't disappear—they eventually show up in pricing.

One of my biggest regrets: not asking about IP disputes during vendor due diligence. The goodwill I'm working with now from a vendor that weathered a patent challenge took three years to develop, but I should have considered it from the start.

Dimension 3: The Total Cost of Vendor Risk

Let's get specific with numbers. Say you're evaluating two endometrial ablation systems. Vendor A (the market leader) quotes $X per system. Vendor B (the challenger) quotes $X - 15%. You save 15% per unit. But now factor in these potential costs:

• If the challenger loses IP protection and has to redesign: retraining costs for your surgical team, potential downtime while new systems are installed, and the cost of switching back to the market leader's system.
• If the challenger's pricing increases after the verdict: you're locked into a contract, but renewal rates may spike.
• If the challenger's service support deteriorates due to financial constraints: delayed repairs, harder to get parts, longer downtime.

I tracked this over 6 years in a broader procurement context. The 'cheaper' option actually cost us 23% more in total when you account for retraining, service delays, and the eventual switch. The vendor who lists all fees upfront—even if the total looks higher—usually costs less in the end. That's been my experience.

What This Doesn't Tell You (The Nuance)

The verdict doesn't mean Minerva is a bad company or that their products are inferior. It means they lost a patent case. That's one data point, not the full picture. (Think of it this way: Intel and AMD have been suing each other for years, and both are still viable vendors.)

It's tempting to say 'big company wins, small company loses, case closed.' But the 'buy from the market leader always' advice ignores the value of competition and innovation. If you never take a chance on a challenger, you miss out on potential pricing leverage and alternative technology approaches.

What the case should do is add a new dimension to your vendor scorecard: IP stability. I now have a line item in my evaluation template that asks: "Has the vendor been involved in any significant IP disputes, and what was the outcome?"

How to Make This Practical: A Procurement Decision Framework

Based on what this case taught me—and six years of vendor evaluation mistakes—here's how I'd approach comparing Hologic-level vs. Minerva-level vendors going forward:

1. Start with total cost of ownership, not unit price. Factor in potential retraining, service disruption, and switching costs. Ask yourself: what's the worst-case scenario if this vendor loses a patent case?
2. Ask the 'what's NOT included' question. Don't just compare prices. Compare the fine print on IP indemnification, patent litigation clauses, and what happens if a product line is disrupted by a legal ruling.
3. Evaluate the vendor's R&D depth. Look at their patent portfolio, clinical publications, and history of innovation. A company that has 50+ patents in a space is different from one with 2-3. (That's not a judgment—it's a risk factor to price into your decision.)
4. Build a relationship buffer. If you choose the challenger, don't put all your eggs in one basket. Maintain a relationship with the market leader as a backup. Negotiate terms that protect you if the product is discontinued or redesigned.

I still kick myself for not thinking about IP risk three years ago when we were choosing a surgical platform. If I'd asked one more question—'are there any active patent disputes involving your core technology?'—I'd have saved us months of headaches and a budget overrun that I'm still explaining to my CFO.

The Minerva v. Hologic verdict is a reminder that procurement isn't just about price. It's about risk, stability, and long-term partnership. The best deal on paper isn't always the best deal in practice.